Abstract: The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.
Abstract: The invention provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
Type:
Grant
Filed:
July 22, 2021
Date of Patent:
December 5, 2023
Assignee:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Inventors:
Christoph Rader, Haiyong Peng, Xiuling Li
Abstract: The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
Type:
Grant
Filed:
August 31, 2022
Date of Patent:
November 28, 2023
Assignee:
Biogen MA Inc.
Inventors:
Isin Dalkilic-Liddle, Benjamin A. Smith, Karl J. M. Hanf, Fang Qian, R. Blake Pepinsky, Thomas O. Cameron
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
Type:
Grant
Filed:
April 30, 2021
Date of Patent:
November 28, 2023
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf
Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
Type:
Grant
Filed:
February 3, 2021
Date of Patent:
November 21, 2023
Assignees:
Rigshospitalet, University of Copenhagen
Inventors:
Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
October 31, 2023
Assignees:
Tusk Therapeutics Ltd., Cancer Research Technology Limited
Inventors:
Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
Abstract: This disclosure relates to biomarkers for Age-Related Macular Degeneration (AMD) and methods of use thereof, e.g., methods of the use of biomarkers for determining that a subject has Age-related Macular Degeneration (AMD) or determining the stage of AMD in a subject.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
October 17, 2023
Assignee:
Massachusetts Eye and Ear Infirmary
Inventors:
Ines Maria de Carvalho Lains, Deeba Husain, Joan W. Miller
Abstract: Provided are bifunctional molecules that include a first moiety that specifically binds a cell surface molecule or extracellular molecule, and a second moiety that specifically binds a lysosomal targeting molecule. The bifunctional molecules find use, e.g., for targeted degradation of cell surface and extracellular molecules (e.g., proteins) via the endosomal/lysosomal pathway. Also provided are compositions and kits that include the bifunctional molecules, as well as methods of using the bifunctional molecules. Methods of making bifunctional molecules are also provided.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
October 17, 2023
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Carolyn Bertozzi, Steven Banik, Kayvon Pedram, Green Ahn
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
October 17, 2023
Assignees:
Tusk Therapeutics Ltd., Cancer Research Technology Limited
Inventors:
Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
Type:
Grant
Filed:
April 3, 2018
Date of Patent:
October 10, 2023
Inventors:
Mark Throsby, Cecilia Anna Wilhelmina Geuijen, David Andre Baptiste Maussang-Detaille, Ton Logtenberg
Abstract: The present disclosure provides a technique for producing regulatory T cells specific to a desired antigen. Regulatory T cells specific to an antigen are produced by a method that includes: a step for identifying a T cell receptor (TCR) clone present in an effector T cell population specific to an antigen in an effector T cell donor; and a step for introducing all or part of the nucleic acid sequence of the TCR? gene and all or part of the nucleic acid sequence of the TCR? gene included in the clone into a regulatory T cell, said step comprising introducing the TCR? and the TCR? so as to be expressed in pairs.
Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.
Type:
Grant
Filed:
August 9, 2018
Date of Patent:
October 3, 2023
Inventors:
Cecilia Anna Wilhelmina Geuijen, Robertus Cornelis Roovers, Mark Throsby, Cornelis Adriaan De Kruif, Ton Logtenberg
Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a chimeric antigen receptor (CAR) capable of binding human PSCA. CARs capable of binding human PSCA, and nucleic acids encoding the same are also provided. Provided herein are bispecific CARs capable of binding human PSCA and human PSMA, nucleic acids encoding the same, and modified immune cells comprising the same. Modified immune cells comprising a PSMA CAR and a PSCA CAR are also provided. Compositions and methods of treatment are also provided.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
September 26, 2023
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.
Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a feline and methods of their use. The compositions involve variant feline IgG Fc regions.
Type:
Grant
Filed:
April 29, 2022
Date of Patent:
August 29, 2023
Assignee:
Invetx, Inc.
Inventors:
William Brondyk, Brett Chevalier, Juergen Horn, Madhusudan Natarajan
Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.
Type:
Grant
Filed:
September 10, 2018
Date of Patent:
August 29, 2023
Assignee:
NATIONAL RESEARCH COUNCIL OF CANADA
Inventors:
Kevin Henry, Maria Luz Jaramillo, Colin Roger Mackenzie, Anne Marcil
Abstract: This invention provides new antibodies (Ab) and fragments that recognize the extracellular region of the human epidermal growth factor receptor (hEGFR) with a higher affinity than the Ab nimotuzumab, thus been able to recognize more efficiently lines with medium expression of EGFR. The present invention also relates to pharmaceutical compositions comprising as active principle the disclosed Abs and fragments and their use in the therapy of tumors with EGFR expression. In addition, it relates to the use of the Abs and fragments disclosed linked to a radioisotope or fluorophore for the localization of EGFR positive tumors. Additionally, the Abs and fragments disclosed can be used in the directionalization of the immune response to EGFR positive tumor cells when they are fused to protein or protein domains of immunological interest.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
August 8, 2023
Assignee:
CENTRO DE INMUMOLOGIA MOLECULAR
Inventors:
Yaima Tundidor Cabado, Gertrudis Rojas Dorantes, Kalet Leon Monzon
Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
Abstract: The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to a ligand and may improve immunotherapy by limiting side effects associated with immunotherapy.
Type:
Grant
Filed:
August 18, 2020
Date of Patent:
August 1, 2023
Assignee:
Washington University
Inventors:
Alexander Sasha Krupnick, Eric Reed Lazear, Daved Henry Fremont